Aurinia Pharmaceuticals (AUPH) Gross Margin (2020 - 2026)
Aurinia Pharmaceuticals (AUPH) reported Gross Margin of 91.63% for Q1 2026, up 535.0% on a YoY basis from 14.43% in Q1 2025, and up 3.43% quarter-over-quarter from 88.59% in Q4 2025.
Aurinia Pharmaceuticals (AUPH) Gross Margin (2020 - 2026) Analysis & Trends
Aurinia Pharmaceuticals has reported Gross Margin for 7 years, with the latest figure at 91.63% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin rose 535.0% year-over-year to 91.63%; the trailing twelve-month figure through Mar 2026 stood at 89.74% (up 150.0% YoY), and the FY2025 full-year result was 88.46%, up 47.0% from the prior year.
- Gross Margin for Q1 2026 stood at 91.63%, up from 88.59% in the prior quarter.
- The five-year high for Gross Margin was 98.82% in Q1 2022, with the low at 84.42% in Q2 2024.
- Historically, Gross Margin has averaged 91.21% across 5 years, with a median of 90.73% in 2024.
- Annual changes were most pronounced in 2024 — Gross Margin slumped 1419 bps — and 2025, when it jumped 541 bps.
- Aurinia Pharmaceuticals' Gross Margin stood at 95.21% in 2022, then declined by 8 bps to 88.04% in 2023, then rose by 3 bps to 90.73% in 2024, then decreased by 2 bps to 88.59% in 2025, then rose by 3 bps to 91.63% in 2026.
- The last three Gross Margin figures came in at 91.63% (Q1 2026), 88.59% (Q4 2025), and 88.87% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 79.04% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Aurinia Pharmaceuticals | 2.18 Bn | 1.80 Bn | 71.20 Mn | 91.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91.63% |
| Dec 31, 2025 | 88.59% |
| Sep 30, 2025 | 88.87% |
| Jun 30, 2025 | 89.84% |
| Mar 31, 2025 | 86.27% |
| Dec 31, 2024 | 90.73% |
| Sep 30, 2024 | 91.10% |
| Jun 30, 2024 | 84.42% |
| Mar 31, 2024 | 84.59% |
| Dec 31, 2023 | 88.04% |
| Sep 30, 2023 | 87.58% |
| Jun 30, 2023 | 96.23% |
| Mar 31, 2023 | 98.78% |
| Dec 31, 2022 | 95.21% |
| Sep 30, 2022 | 95.61% |
| Jun 30, 2022 | 94.33% |
| Mar 31, 2022 | 98.82% |
| Dec 31, 2021 | 97.94% |
| Sep 30, 2021 | 98.27% |
| Jun 30, 2021 | 95.35% |